The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. TFF Pharmaceuticals Inc. shares valued at $53,000 were purchased by Weisman Harlan F on Dec 15. At $1.06 per share, Weisman Harlan F acquired 50,000 shares. The insider’s holdings grew to 64,615 shares worth approximately $47168.95 following the completion of this transaction.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Also, Fletcher Aaron G.L. purchased 43,470 shares, netting a total of over 49,990 in proceeds. Following the buying of shares at $1.15 each, the insider now holds 143,470 shares.
Before that, THURMAN RANDY H had sold 40,255 shares from its account. In a trade valued at $172,694, the Director traded TFF Pharmaceuticals Inc. shares for $4.29 each. Upon closing the transaction, the insider’s holdings decreased to 40,255 shares, worth approximately $0.0.
Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in early February. As of December 07, 2020, B. Riley Securities has initiated its “Buy” rating for TFFP. Earlier on August 17, 2020, Maxim Group resumed its rating. Their recommendation was “a Buy” for TFFP stock.
Analyzing TFFP Stock Performance
On Thursday, TFF Pharmaceuticals Inc. [NASDAQ: TFFP] rose 17.36% to $0.73. The stock’s lowest price that day was $0.62, but it reached a high of $0.7628 in the same session. During the last five days, there has been a drop of approximately -18.54%. Over the course of the year, TFF Pharmaceuticals Inc. shares have dropped approximately -30.58%. Shares of the company reached a 52-week high of $1.1300 on 01/11/23 and a 52-week low of $0.6200 on 02/23/23. A 50-day SMA is recorded $0.9447, while a 200-day SMA reached $3.5028. Nevertheless, trading volume fell to 0.7 million shares from 0.37 million shares the previous day.
Support And Resistance Levels for TFF Pharmaceuticals Inc. (TFFP)
According to the 24-hour chart, there is a support level at 0.6450, which, if violated, would cause prices to drop to 0.5611. In the upper region, resistance lies at 0.7878. The next price resistance is at 0.8467. RSI (Relative Strength Index) is 36.57 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.1883, which suggests the price will decrease in the coming days. Percent R is at 70.57%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
Is TFF Pharmaceuticals Inc. subject to short interest?
Stocks of TFF Pharmaceuticals Inc. saw a sharp steep in short interest on Jan 30, 2023 dropping by 72060.0 shares to 0.48 million. Data from Yahoo Finance shows that the short interest on Dec 29, 2022 was 0.55 million shares. A decline of -15.02% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5.21 of the overall float, the days-to-cover ratio (short ratio) decline to 5.21.
Which companies own the most shares of TFF Pharmaceuticals Inc. (TFFP)?
According to AIGH Capital Management LLC filings, the company currently owns 1,739,130 shares, which is about 4.81% of the total TFFP shares outstanding. With the completion of the buy transaction, Carlson Capital LP’s stake is now worth $1,155,060. A total of 427,824 shares of TFF Pharmaceuticals Inc. were sold by Worth Venture Partners LLC during the quarter, and 15,540 were bought by Sepio Capital LP. In its current portfolio, BlackRock Fund Advisors holds 255,637 shares valued at $0.24 million.
In terms of TFF Pharmaceuticals Inc. share price expectations, FactSet research, analysts set an average price target of $18.00 in the next 12 months, up nearly 2803.23% from the previous closing price of $0.62. Analysts anticipate TFF Pharmaceuticals Inc. stock to reach $22.00 by 2023, with the lowest price target being $14.00. In spite of this, 2 analysts ranked TFF Pharmaceuticals Inc. stock as a Buy at the end of 2023. On July 08, 2020, Maxim Group assigned a price target of “a Buy” to the stock and initiated coverage with a $12.